Features

657 Features
How to stop recruiters throwing out your CV

20 Jan 12

Recruiters are very busy people, and typically have little time to read and select CVs for any given role. For them it’s a filtering process, often starting with a pile of CV’s and throwing out the bad ones before reading in more detail, the ones that are left. Therefore your task is NOT to get thrown out with the bathwater, and ensure that your CV is one of the ones that makes it past the first cull!
Mike Wood

Working while on holiday-survey results

04 Oct 11

We recently ran a survey to ask people about the work they do when they are on vacation. It makes interesting reading!
Mike Wood

NICE - Analyst and Adviser Opportunities

03 Oct 11

NICE is a world-renowned, independent organisation responsible for providing national recommendations on the use of new and existing medicines and treatments within the NHS, through the Technology Appraisal Programme. The Scientific Advice Programme provides not-for-profit chargeable consulting services to companies who have products in development that may be referred for future evaluation by NICE.
NICE

Working while on Holiday?

25 Aug 11

How common is it to work during your vacation? - Take our short survey.
Mike Wood

The Long-term Costs of Health Care

17 Aug 11

Almost irrespective of the country you live in, the increasing costs of healthcare are unavoidable. For governments, the stresses are particularly acute, as both aging populations and the increasing cost of treatments add financial pressures year on year. Yet as a new study by the Institute of Fiscal Studies (IFS) confirms, we should not underestimate the extent to which the shape of the state has already changed.
Max Golby - PharmiWeb Field Reporter

Let the jobs come to you!

04 Aug 11

Find out about the latest jobs that match your search - automatically.
Mike Wood

Pharma on Twitter

14 Apr 11

Want to know which Pharma companies are on Twitter? - here's a list..
Mike Wood

Sanofi-aventis to Acquire Genzyme

24 Feb 11

After six months of sometimes lively pursuit, the French pharmaceutical group, Sanofi-aventis, has agreed a deal to pay $20.1bn in cash for U.S. biotech firm Genzyme Corp after Sanofi made an increased offer of $74 per share.
Max Golby - PharmiWeb Field Reporter

Hold onto Your Top Talent Using Social Media

22 Feb 11

Social networking sites such as Facebook, Linkedin and Twitter are all the rage – there’s no escaping them, they’re everywhere – even in the workplace, and whether you like it or not, they’re not going away.
Catherine Gutsell, CK Group

9 Point Pre-Interview Checklist

18 Feb 11

If you've got your self an interview for the perfect job - well done! Now comes the hard part, and you only get one chance. So, here's a simple check list of things that should help you keep your cool and allow you to concentrate on sailing through the interview
Mike Wood

How to | Get a job in Pharma using PharmiWeb.com

07 Feb 11

If you are new to using PharmiWeb.com to find a new job, you'll soon realise that we have thousands of jobs listed and that they change every day. This means you may initially find the task a bit daunting. However, it’s not really that hard, and with a bit of thought, you will soon be asking why you didn’t do it years ago.
Mike Wood

BrightTALK™ Digital Marketing and Pharma Summit

11 Nov 10

As patients and prescribers increasingly move online for their information, how can pharma engage these audiences by incorporating digital marketing into their current plans?
Mike Wood

US Prescription Drug Use- The Rise and Rise

16 Sep 10

As healthcare innovation produces new treatments, and new information delivers increased awareness, a substantial rise in prescription drug use is only to be expected. For the most part, this can largely be seen as a positive development.
Max Golby

Stem Cell Research: The Politics of Science

09 Sep 10

Potentially lifesaving science should not be marginalized to the status of a political football. Yet for so many years in the United States, that’s exactly what stem cell science has become.
Max Golby

Career Opportunities in Clinical Drug Research

07 Sep 10

A new book by Rebecca J. Anderson
Mike Wood

Quick Look: Dementia

02 Sep 10

Even in the good years, mental health budgets were seldom in line with what experts expected or deemed necessary. Thus, in times of budget deficits and scathing public expenditure cuts, the worry becomes even greater. For those that care most about the health service then, the Coalition government's decision to ring fence healthcare spending has been largely applauded.
Max Golby

PFI Hospitals: Reality Hits

25 Aug 10

Originally born under the Conservatives, but fully evolved under Labour, Private Finance Initiatives (PFIs) essentially offered the NHS an alternative way of paying for new hospitals and renovations at a time when public capital was said to be limited.
Max Golby

Hospitality or Bribery? U.S. Pharma under the Spotlight

23 Aug 10

While long prohibited under UK ABPI regulations, if you’ve worked in the world of big pharma in the U.S., you’ll have seen it all a hundred times. A drugs company sponsors a medical conference, they pay for the meals and flights of the delegates and they hand them all a goodie bag as they leave.
Max Golby

CRT AND ValiRx SIGN LICENSING DEAL TO DEVELOP PROSTATE CANCER TREATMENT

12 Aug 10

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.
Cancer Research UK

Worst Possible Interview Mistakes

23 Jul 10

If the nation’s recruiters received a pound for every time they’d interviewed a candidate that looked good on paper but disappointed in practice, there’d currently be an awful lot of recruiters in the process of relocating to the Caribbean.
Max Golby / Mike Wood

Increasing numbers of deaths from malignant melanoma should be prevented by early detection and protection from ultraviolet rays

20 Jul 10

Skin cancers come in various forms but the type which causes most fear is the malignant melanoma, derived from the pigment-forming cells of the skin or melanocytes.
Dr Laurence Lever

The Research Revolution

19 Jul 10

During a time of major economic downturn, there are few industries that can be said to be truly ‘recession proof’. Yet for years now, big pharma has largely been seen as precisely that. After all, no matter dire the markets, and no matter how low consumer confidence plummets, there is always a demand for healthcare.
Max Golby

NHS Targets

25 Jun 10

In areas such as competition policy and choice in the NHS, there could be said to be much correlation between the approaches of both governments past and present. Yet in other key areas of policy, there are unquestionably examples of ideological, or at least philosophical, differences in outlook. Or at least in theory.
Max Golby

Swine Flu Hoax

18 Jun 10

A selective memory is a wonderful thing. That is, if you're a conspiracy theorist or an opportunistic critic of any kind. Yet, for those of us with memories of a more consistent mold, a lot of the current and decidedly harsh criticism directed against the World Health Organization’s handling of the just passed H1N1 'Swine Flu' outbreak must be questioned in kind.
Max Golby

Competition in the Health Service

17 Jun 10

As the new Conservative-led coalition finally begins to settle down to the task ahead, questions of policy detail are increasingly replacing the brouhaha of election-time buccaneering and healthcare policy and the NHS are no exceptions to the rule – particularly in the case of competition policy.
Max Golby

A Very Human Response to the Recession

28 May 10

With every challenge comes a new opportunity. Indeed, if we are to believe the results of a recent international workforce survey by Kelly Services, while the global economic recession has produced troubles a plenty, it has also evoked a new found sense of entrepreneurialism as workers look to adjust to changing employment models and to respond to new challenges in a very human way.
Max Golby

Astellas Pharma five year anniversary: Past success, future thinking

28 May 10

Just five years after its formation through the merger of Fujisawa and Yamanouchi, Astellas has become one of the top 20 pharmaceutical companies in the world. Employing 15,000 people and with annual sales reaching €1,287 million in Europe, Astellas has exceeded all expectations for growth in the past five years and the company’s management team has devised a clear vision to ensure that this success continues in the years to come.
Astellas Pharma

New wave of independent, self-employed free agents emerging around the world, Kelly® international workforce survey finds

20 May 10

Economic uncertainty has fueled a growing trend toward self-employment and entrepreneurialism with one-in-five respondents worldwide now working outside the traditional employment relationship, and 50 percent saying that they would like to do so, according to the latest survey results from workforce solutions leader Kelly Services®.
Editor

Study Gives Better Understanding Of How Reoviruses And Chemo Work Together

13 May 10

Researchers at Weill Cornell Medical Center in New York have demonstrated that a reovirus therapy called REOLYSIN works synergistically with gemcitabine and may be worth further investigation.
Janet Vasquez

Karolinska Institutet report findings - Personalised Medicine and future healthcare delivery

22 Apr 10

Karolinska Institutet is one of the world´s leading medical universities. Its mission is to contribute to the improvement of human health through research and education. Karolinska Institutet accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country´s broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
Alex Heeley - De Facto Communications